Update study of GLP-1 receptor agonist in the treatment of non-alcoholic fatty liver disease / 天津医药
Tianjin Medical Journal
; (12): 1230-1234, 2015.
Article
en Zh
| WPRIM
| ID: wpr-481518
Biblioteca responsable:
WPRO
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases across the world, but there is still no specific treatment for NAFLD. Glucogon-like peptide 1 receptor agonist (GLP-1Ra) is a novel drug for the treatment of type 2 diabetes, based on incretin hormone target. Animal and clinical studies have demonstrated that GLP-1Ra can effec?tively reduce fat deposit in liver and attenuate hepatic steatosis. Therefore, GLP-1Ra is a promising therapeutic approachagainst NAFLD. In this review, we provided an overview of the clinical and basic research evidences and mechanisms in re?lieving NAFLD.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Tianjin Medical Journal
Año:
2015
Tipo del documento:
Article